Page last updated: 2024-12-05
2-acetamidoethanethiol
Description
2-Acetamidoethanethiol, also known as N-acetylcysteine (NAC), is a naturally occurring amino acid derivative. It is synthesized commercially by reacting cysteine with acetic anhydride. NAC is a potent antioxidant, protecting cells from damage caused by free radicals. It is widely used as a mucolytic agent to thin mucus in respiratory diseases like cystic fibrosis and chronic obstructive pulmonary disease (COPD). Additionally, NAC is used to treat acetaminophen overdose, as it helps replenish glutathione levels, a critical antioxidant in the liver. Its ability to increase glutathione levels also makes it a promising agent in various other conditions, including cancer, HIV infection, and neurodegenerative diseases. Research on NAC focuses on understanding its antioxidant mechanisms, exploring its therapeutic potential in different diseases, and investigating its safety and efficacy in various clinical settings.'
2-acetamidoethanethiol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
N-acetylcysteamine : A member of the class of acetamides that is the N-acetyl-deriavtive of cysteamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 14484 |
CHEBI ID | 74410 |
SCHEMBL ID | 474178 |
MeSH ID | M0081247 |
Synonyms (46)
Synonym |
n-acetyl cysteamin |
cysteamine, n-acetyl- |
n-acetylcysteamine |
ethanethiol, 2-(acetylamino)- |
n-(2-mercaptoethyl)acetamide |
nsc38835 |
nsc-38835 |
2-acetamidoethanethiol |
wln: sh2mv1 |
acetylcysteamine |
acetamide, n-(2-mercaptoethyl)- |
1190-73-4 |
acetamide, n-(.beta.-mercaptoethyl)- |
n-acetylmercaptoethylamine |
n-acetyl cysteamine |
brn 1743117 |
nsc 38835 |
acetamide, n-(beta-mercaptoethyl)- |
cysteamine,n-acetyl |
n-acetyl cysteamin [german] |
n-acetylcysteamine, 95% |
n-(2-sulfanylethyl)acetamide |
FT-0693701 |
thiol n-acetyl-beta-mercaptoethylamine |
nsh3f3jx85 , |
4-04-00-01607 (beilstein handbook reference) |
n-acetyl-beta-mercaptoethylamine |
unii-nsh3f3jx85 |
AKOS006223010 |
CHEBI:74410 |
n-(2-mercaptoethyl)-acetamide |
n-(2-mercapto-ethyl)-acetamide |
2-acetylaminoethyl mercaptan |
SCHEMBL474178 |
acetamide n-(2-mercaptoethyl)- |
n-(2-sulfanylethyl)acetamide # |
DTXSID90152289 |
J-004064 |
AS-60537 |
AT13754 |
Q27144656 |
n-acetyl-.beta.-mercaptoethylamine |
mfcd00037831 |
A892671 |
EN300-211454 |
SY117216 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
acetamides | Compounds with the general formula RNHC(=O)CH3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.53 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |